Fulcrum Therapeutics, Inc. (FULC)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | - | - | - | |
| Restructuring expenses | - | - | 2,063 | |
| Research and development | 12,987 | 13,404 | 14,639 | |
| General and administrative | 6,828 | 6,999 | 8,424 | |
| Total operating expenses | 19,815 | 20,403 | 25,126 | |
| (loss) income from operations | -19,815 | -20,403 | -25,126 | |
| Other income, net | 2,519 | 2,748 | 3,430 | |
| Net (loss) income | -17,296 | -17,655 | -21,696 | |
| Earnings per share, basic | -0.28 | -0.28 | -0.35 | |
| Earnings per share, diluted | -0.28 | -0.28 | -0.35 | |
| Weighted-average common shares outstanding, basic | 62,544,000 | 62,479,000 | 62,409,000 | |
| Weighted-average common shares outstanding, diluted | 62,544,000 | 62,479,000 | 62,409,000 | |